Myriad Ruling Vs. Biotech Patent Eligibility In Europe

Law360, New York (June 21, 2013, 7:00 PM EDT) -- Companies investing in biotechnology understand that while returns can be enormous, the path toward approval of new biotechnological products is long, arduous and, most of all, expensive. With aging populations and decreases in the governmental resources set aside for their care, reimbursement for health services is becoming more difficult to obtain. Moreover, the implementation of pharmaceutical price controls in many developed nations is on the rise. In a difficult financial environment, these factors are increasingly impacting the biotechnology investment formula and business model.

Recent high-profile decisions...
To view the full article, register now.